A high-throughput platform for neo-antigen based cancer immunotherapy
Award amount
$299,917Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ImmuDX LLC
- Proposal award date
- 2018-08-01
- Contract end date
- 2019-07-31
- UEI
- D6NRPST2VJH5
- Solicitation number
- PA17-302
- Topic code
- 100
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Research funding history
2 SBIR/STTR records share this UEI (2018). Reported award amounts total $882,444. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services